Navigation Links
Perrigo Provides Update on Acquisition of Paddock Labs
Date:6/29/2011

ALLEGAN, Mich., June 29, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that it continues to work to finalize  the regulatory approvals necessary to complete the acquisition of Paddock Laboratories, Inc. ("Paddock"), a privately-held, Minneapolis-based pharmaceutical manufacturer of generic Rx pharmaceuticals and OTC specialty products.

Perrigo Chairman and CEO Joseph C. Papa stated, "We are looking forward to concluding the transaction as soon as possible. As we previously stated, we expect the transaction to be $0.25 accretive to adjusted earnings per share in fiscal year 2012. We have recently received a few additional questions from the Federal Trade Commission Staff and the Parties are working collaboratively with the Staff to answer these questions so that the FTC may conclude its review.  Since the close will now happen in our fiscal year 2012, we expect to incur $0.20 of deal-related intangible amortization and $0.15 of other acquisition-related costs, making it approximately $0.10 dilutive to GAAP earnings per share. Perrigo's stated goal of Return on Invested Capital accretion is expected to be achieved in fiscal 2013. This acquisition is an important step forward in executing Perrigo's strategy to expand our specialty portfolio of generic Rx products. It adds incremental scale, as well as excellent development and manufacturing capabilities across a spectrum of niche dosage forms. It solidifies Perrigo's leading position in the extended topical space and strengthens our ability to offer new products into the market. Paddock has a proven record for quality manufacturing with great customer service."

As previously highlighted, Perrigo expects to receive a significant tax benefit generated from the acquisition of Paddock's assets. The net present value of the tax benefit is estimated to be $95 million. Inclusive of the tax benefit, the total consideration for the acquisition is approximately $445 million
'/>"/>

SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Perrigo Announces Launch of the Generic Version of Nasacort® AQ
2. Perrigo Company to Present at the Goldman Sachs 32nd Annual Global Health Care Conference
3. Perrigos Partner Synthon Receives FDA Tentative Approval for Levocetirizine Solution - Generic Equivalent to Xyzal® Oral Solution
4. Perrigo Announces FDA Final Approval for Ranitidine 150 - Generic Equivalent to Zantac 150®
5. Perrigo Announces Settlement of Cutivate Lotion Litigation
6. Perrigo to Introduce New Dosing System and Labeling for Certain Pediatric Pain Relievers
7. Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance
8. Perrigo Announces FDA Final Approval for Minoxidil Foam - Generic Equivalent to Mens Rogaine® Foam
9. Perrigo Company Announces Quarterly Dividend
10. Perrigos PBM Infant Formula Unit Wins Appellate Judgment Versus Mead Johnson
11. Perrigo Partner Teva Receives Final OTC Approval for Sales and Distribution of Fexofenadine HCl 60 mg and 180 mg Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... July 23, 2014 /PRNewswire-iReach/ -- Top Staten Island Pediatrician ... his feedback on article, which discusses tips for parents about ... According to US News ... death among American children aged 1 to 4, and can ... One expert in the article says that watching a ...
(Date:7/23/2014)... July 23, 2014 Inovio Pharmaceuticals, ... results from its randomized, double-blind, placebo-controlled phase ... biopsy-proven cervical intraepithelial neoplasia 2/3 (CIN2/3) associated ... 18. Treatment with VGX-3100, Inovio,s HPV16/18-specific immunotherapy, ... CIN1 or no disease, meeting the study,s ...
(Date:7/23/2014)... , July 23, 2014  The management team ... ) will hold a conference call on July ... second quarter ended June 30, 2014.  The call ... 2014Time: , 8:30 am EDTDial-in numbers: , Toll ... (412) 317-0790Webcast (live & archive): , www.columbialabs.com ...
Breaking Medicine Technology:Premier Staten Island Pediatrician Dr. Michael Gabriel Comments On Article Discussing Pool Safety Tips for Parents 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 3Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 4Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 5Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2
... , PALO ALTO, Calif., Dec. 2 ... 25, 2009, Varian, Inc. filed with the U.S. Securities and Exchange ... ended October 2, 2009. This Annual Report may be accessed ... and "SEC Filings," and then on "10-K" in the table shown. ...
... , ST. LOUIS, Dec. 2 KV Pharmaceutical Company ... an employment agreement with Interim President and Chief Executive Officer ... 2011. Mr. Van Vliet has served as Interim President and ... provides continuity of senior leadership as the Company seeks to ...
Cached Medicine Technology:KV Pharmaceutical Enters Into Employment Agreement with Interim President and Chief Executive Officer David A. Van Vliet 2
(Date:7/23/2014)... ( FXS ) is a genetic disorder that causes ... autistic spectrum, as well as cognitive deficits. It is ... the most common cause of autism. , Now biomedical ... a study that sheds light on the ... (July 23) in the Journal of Neuroscience , ...
(Date:7/23/2014)... Kathleen Doheny HealthDay Reporter ... surgery appears to have an additional side benefit -- ... to a new study. The study found that ... reported having incontinence prior to the procedure. After surgery, ... improved or disappeared, said study researcher Dr. Leslee Subak, ...
(Date:7/23/2014)... the genome resulting from a combination of genetic modifications ... weak predispositions to developing certain kinds of cancer; in ... throughout our lifetime. Although the genetic origins of cancers ... not able to measure the role of non-coding regions ... from the University of Geneva (UNIGE), by studying tissues ...
(Date:7/23/2014)... 2014 A therapy combining salmon fibrin injections into ... into the brain restored voluntary motor function impaired by ... Center have found. , In a study on rodents, ... turning back the developmental clock in a molecular pathway ... and providing a scaffold so that neuronal axons at ...
(Date:7/23/2014)... Recently, Agebc.com has launched its new collection of ... a promotion of wedding dresses. According to a representative ... end of this month. , The beautiful wedding dresses ... mermaid, ball-gown, empire, and more. Agebc.com is a well-known ... for women, and the company is devoted to providing ...
Breaking Medicine News(10 mins):Health News:Study links enzyme to autistic behaviors 2Health News:Study links enzyme to autistic behaviors 3Health News:Weight Loss Surgery May Help Ease Urinary Incontinence 2Health News:Weight Loss Surgery May Help Ease Urinary Incontinence 3Health News:Genetics of cancer: Non-coding DNA can finally be decoded 2Health News:Gene inhibitor, salmon fibrin restore function lost in spinal cord injury 2Health News:Agebc.com Launched Its New Collection of Wedding Dresses 2
... ... beings need music as a form of release and expression, and now it has been ... ... stressors, stimuli, and distractions in this world, it can be difficult for the average person ...
... Huge ... ... Almac has addressed ongoing industry developments by greatly expanding their capacity in the New ... in the pharmaceutical industry, specifically the growing demand for biologics. Biologics, which are ...
... ... announced today it has acquired Canterbury International, a privately-held company based ... furnishings. The Verdin Company, based in Cincinnati, Ohio, is recognized ... and clock towers, glockenspiels, and other musical instruments.,Canterbury International, a leading ...
... ... and Profitability. , ... Manasquan, NJ, USA (PRWEB) June 21, 2010 -- Marketers with sufficient insight to estimate ... untapped profit potential, according to the 2010 Lenskold Group / emedia Lead ...
... ... industry. Anyone who can understand this contradiction, will understand the sense of urgency related to ... now, keeping BP’s oil spill and the effects of it in mind. , ... (PRWEB) June 20, 2010 -- BP’s oil ...
... ... profession will come together to share knowledge and explore innovations in one of the most ... ... unique conferences offering high-quality scientific programs, which broaden perspectives by exploring the latest innovations in ...
Cached Medicine News:Health News:Reinvent your Mental State With Brainwave Entrainment Relaxation Music 2Health News:Reinvent your Mental State With Brainwave Entrainment Relaxation Music 3Health News:Reinvent your Mental State With Brainwave Entrainment Relaxation Music 4Health News:Almac's US Headquarters Will Address Capacity Demand for Clinical Supplies 2Health News:The Verdin Company Acquires Canterbury International, an industry leader in architectural site furnishings for over 50 years 2Health News:The Verdin Company Acquires Canterbury International, an industry leader in architectural site furnishings for over 50 years 3Health News:Lead Generation Marketing ROI Study Released 2Health News:Lead Generation Marketing ROI Study Released 3Health News:Lead Generation Marketing ROI Study Released 4Health News:Wind turbines harmful for the environment and public health 2Health News:The 2nd Future Trends in Implantology International Dental Conference 2
Diamond Filter Tips play a critical role in preventing aerosol-borne contamination. Also available sterilized (no need to autoclave) and certified free of detectable RNase, DNase, DNA, RNA, and prote...
10 L, Racked, Pre-sterilized, 96 tips/rack Recommended for 2, 5 and 10 L pipettes....
... are ideal for PCR and ... any work where aerosol contamination ... for pipetting DNA/RNA solutions, infectious ... For applications requiring absolute sterility, ...
Avant E-Z Rack Premium Low Binding 10 l Pipet Tips are accurate, contamination free, and allow quantitative transfer of your samples without relying on silicone....
Medicine Products: